



PRESS RELEASE

JSC Servier enters into Agreement with Daiichi Sankyo Europe GmbH for Factor Xa Inhibitor LIXIANA® (edoxaban)

Moscow, April 19, 2017 – JSC “Servier” is pleased to announce the signing of a strategic agreement with Daiichi Sankyo Europe GmbH. Under this agreement, JSC “Servier” will package the oral, once-daily anti-coagulant, edoxaban, at its manufacturing site in Moscow (Russia) and then commercialize it in Albania, Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Montenegro, Russia, Serbia, Tajikistan, Turkmenistan, Ukraine, Uzbekistan following approval by Regulatory Authorities.

Edoxaban is an oral once daily novel anti-coagulant treatment that specifically inhibits factor Xa of the coagulation pathway that leads to blood clotting that was discovered and developed by Daiichi Sankyo Co., Ltd. In Europe, edoxaban is indicated for the prevention of stroke and systemic embolic events in patients with nonvalvular atrial fibrillation (NVAf), as well as for the treatment of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as prevention of recurrent VTE. This current filing in this strategic agreement will be based on a worldwide clinical development program that includes two phase 3 clinical studies, ENGAGE AF-TIMI 48 and Hokusai-VTE. Edoxaban is currently marketed as LIXIANA® in Japan, South Korea, Hong Kong, Taiwan, Thailand, Switzerland, the U.K., Germany, Ireland, the Netherlands, Italy, Spain, Belgium, Austria, Portugal, and other European countries.

“In our daily activities we are committed to therapeutic progress to benefit patients. As edoxaban fits well in our current portfolio, I am convinced that it will take a worthy place there and will contribute to improve treatment outcomes for people with cardiovascular diseases (CVD) and accordingly increase their life expectancy and improve their quality of life,” underlined Jerome Gavet, Managing Director, Servier Russia and EAEU countries.

Oliver Appelhans, Senior Vice President Daiichi Sankyo Europe GmbH also emphasized: “We are pleased to partner with JSC Servier Russia, a well-established and respected organization with extensive expertise in marketing cardiovascular products in Russia and CIS countries”.

About Servier Group:

Servier is an international pharmaceutical company governed by a non-profit foundation with its headquarters in Suresnes (France). With a strong international presence in 148 countries and a turnover of 4 billion euros in 2016, Servier employs 21 000 people worldwide. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular diseases, diabetes, cancers, immune-inflammatory diseases, and neurodegenerative diseases, as well as by its activities in high-quality generic drugs. Being completely independent, the Group reinvests 25% of turnover (excluding generics) in research and development and uses all its profits for growth.

A key player in cardiology and hypertension for the last 20 years, number 2 in Europe and 8 worldwide, Servier has 12 major products on the market with a total turnover of more than 1.6 billion euro in 2016. Currently, there are 12 new fixed-dose combinations and 10 new molecular entities

in research or development, mainly targeting heart failure. This portfolio of innovative treatments is being developed with partners worldwide.
For more information visit www.servier.com.

About Servier Russia:

Servier has been active in Russia for 25 years, where it is one of the leading pharmaceutical companies. In 1999, the company established its Russian Center for Therapeutic Research in Moscow. In 2007, a high-tech pharmaceutical plant opened in Russia in full compliance with GMP standards. Today it is a full-scale plant producing original medicines intended for treatment of major non-communicable diseases for Russian citizens. In 2012 Servier became one of the first international companies to start exporting its products produced in Russia to the CIS countries. For more information visit www.servier.ru

About Daiichi Sankyo Group:

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a "Global Pharma Innovator with a Competitive Advantage in Oncology," Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immunology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit: www.daiichisankyo.com.

Enquiries:

Servier Russia

Yana Kotukhova
Corporate Communication Director EAEU
Tel: +7-495-937-07-00
E-mail: Yana.Kotukhova@servier.com

Servier Group

Karine Bousseau
Servier External Communications
Tel: +33 1 5572 6037
E-mail: media@servier.com

Daiichi Sankyo Europe GmbH

Lydia Worms
Tel: +49 89 7808590
Lydia.Worms@daiichi-sankyo.eu

Forward-looking statements

This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of DAIICHI SANKYO Co., Ltd. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. DAIICHI SANKYO Co., Ltd. Assume no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.